Natera raises 2026 revenue outlook as Signatera drives Q3 growth

Transcript intelligence

What changed

Management raised full-year 2026 revenue guidance to $3.05–$3.35 billion and described plans for Signatera launches in Japan, additional MolDX submissions, and progress toward an FDA submission for the FIND study. The prior-quarter analysis described FY revenue guidance of $2.85–$2.91 billion and the FIND study as enrolling; the current analysis says it is fully enrolled.

Guidance delta

Raised full-year 2026 revenue guidance to $3.05–$3.35 billion; management also set a $6 billion revenue target for 2029. The supplied prior-quarter analysis listed FY revenue guidance of $2.85–$2.91 billion.

Key takeaways

• Q3 revenue was $794 million, up 34% year over year, or more than 40% excluding true-ups, according to the call analysis.
• Management cited strong Signatera volume and ASP improvements; gross margin was around 65%, with underlying organic margin up 140 basis points year over year.
• Medicare coverage for Signatera in early-stage HCC and FDA breakthrough device designation for the multi-cancer early detection assay broaden the clinical and coverage backdrop.
• The call analysis notes a $6 billion 2029 target, while listing execution, expense, margin, and reimbursement questions that remain material.

Management priorities

• Expand Signatera through U.S. coverage submissions and planned launches in Japan for colorectal and muscle-invasive bladder cancers.
• Advance the FIND multi-cancer early detection trial toward FDA submission and scale the Signatera Genome platform.
• Build pharma collaborations and data-licensing services while growing women’s health and transplant monitoring products.